MYGN 241220 18.00C (MYGN241220C18000) Stock Options, News & Quotes

US OptionsDetailed Quotes

MYGN241220C18000

Watchlist

0.40
0.000.00%

15min DelayTrading Nov 22 10:15 ET

0.40High0.40Low

Intraday

5D
Daily

News

Myriad Genetics Expands Partnership With Illumina to Enhance Genomic Profiling for Cancer Detection
Quiver QuantitativeNov 20 16:41 ET
Myriad Genetics Announces The Incorporation Of Its HRD Platform In Illumina's Updated Gene Panel Assay
BenzingaNov 20 16:33 ET
Myriad Genetics Announces Incorporation of Its Proprietary HRD Platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 V2
GlobeNewswireNov 20 16:30 ET
Myriad Genetics Announces Prequel Prenatal Screening Can Now Be Performed Eight Weeks Into Pregnancy
GlobeNewswireNov 19 08:00 ET
Morgan Stanley Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $21
Moomoo NewsNov 18 04:31 ET · Ratings
Life Sciences Stocks Viewed Positively at TD Cowen Despite Post-election Weakness
Seeking AlphaNov 15 15:55 ET

Comments

Trytosaveabit

Mar 20 15:22

Bad sign when a patent granted gets zero attention!

$Myriad Genetics (MYGN.US)$ Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device 16 MINUTES AGO, 4:05 PM EDT VIA GLOBENEWSWIRE

Moomoo AI

Feb 1 08:31

The acquisition is expected to enable Myriad to more effectively scale and grow its tumor profiling offerings to complement its oncology portfolio of hereditary cancer and companion diagnostic testing options.

Press Release: Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory From Intermountain Precision Genomics

Moomoo AI

Jan 30 16:00

Dr. Daneker's leadership is expected to drive innovation, growth, and development of the company's oncology portfolio, including expansions into liquid biopsy and minimal residual disease testing. His experience and track record are anticipated to boost the company's strategy with health systems and large oncology practices.

Press Release: Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

Moomoo AI

Jan 18 17:37

The acquisition is set to spur innovation, growth, and further development of Myriad's oncology portfolio. It will also enhance the scaling and growth of their tumor profiling and liquid biopsy tests, including operational efficiencies, reimbursement benefits and new clinical development opportunities.

Press Release: Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory From Intermountain Precision Genomics

Moomoo AI

Jan 2 06:32

The low P/S ratio for Myriad Genetics is likely due to its subpar revenue performance and limited future growth expectations, which have suppressed its share price. These conditions could hinder a significant rise in the share price in the near future.

Investors Aren't Buying Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues